Autolus Therapeutics presents results from AUTO04 in Phase 1/2 LibrA T1 study

Autolus Therapeutics announces clinical data of AUTO4, a TRBC1-targeting CAR T cell therapy in relapsed/refractory TRBC1-Positive Peripheral T-Cell Lymphoma at the International Conference on Malignant Lymphoma being held June 13 to 17, 2023 in Lugano, Switzerland. The LibrA T1 trial is a single arm, open label, multi-center, Phase 1/2 study evaluating the safety and efficacy of AUTO4, a single dose intravenous CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1-positive selected PTCL. Overall, the treatment was well tolerated with no dose limiting toxicities. In Process A, at the highest dose tested, 4 out of 4 patients achieved a response with 2 out of 4 remaining in ongoing complete metabolic response at 15 and 18-months post-dose, respectively. Presence of CAR T cells in the lymph nodes of patients suggest fast homing of CAR T cells to the tumor site, despite absence in the blood. Efficacy data from Process B was not provided given median follow up is less than3 months. “AUTO4, with its unique targeting mechanism, represents an opportunity for advanced programmed T cell therapies that will make a difference in patients who traditionally suffer from severe immunosuppression as a result of current therapeutic options,” said Dr. Edgar Braendle, Chief Development Officer of Autolus. “This is a trial with a small number of patients, but with all 4 patients at the highest dose in the study achieving a response and 2 out of the 4 remaining in a complete metabolic response beyond 12 months, AUTO4 shows potential to provide a novel therapy option for PTCL patients.”